Dear Healthcare Professional,

Sanofi Pasteur has decided to discontinue production and distribution of Diphtheria and Tetanus Toxoids Adsorbed® (DT) and is withdrawing its licenses in all countries. The decision to discontinue the production of DT is based on the minimal demand and need to optimize industrial capacities to meet public health priorities. This decision is not driven by any concern about safety or immunogenicity of DT. The last lot was manufactured in October 2020 with an expiry date of April 2023. **We expect to exhaust available supply by the end of 2022.**

Diphtheria and Tetanus Toxoids Adsorbed vaccine is indicated for active immunization against diphtheria and tetanus in children 6 weeks through 6 years of age (prior to 7th birthday). Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) vaccine or a DTaP-containing vaccine is recommended for immunization of infants and children 6 weeks through 6 years of age. Diphtheria and Tetanus Toxoids Adsorbed should be used in instances where the pertussis vaccine component is contraindicated. Diphtheria and Tetanus Toxoids Adsorbed is not to be used for treatment of diphtheria or tetanus infection.

Sanofi Pasteur offers a large range of Diphtheria, Tetanus, and acellular Pertussis-containing vaccines that can be used in place of Diphtheria and Tetanus Toxoids Adsorbed® vaccine for primary and booster immunization for children 6-weeks through 6-years of age (Prior to the 7th birthday). **Please visit vaccineshoppe.com to view other available options.**

IMPORTANT SAFETY INFORMATION FOR Diphtheria and Tetanus Toxoids Adsorbed

Diphtheria and Tetanus Toxoids Adsorbed is contraindicated in persons who have had a severe allergic reaction (e.g., anaphylaxis) after a previous dose of Diphtheria and Tetanus Toxoids Adsorbed or any other diphtheria toxoid or tetanus toxoid-containing vaccine, or any other component of Diphtheria and Tetanus Toxoids Adsorbed.

If Guillain-Barré syndrome occurred within 6 weeks of receipt of prior vaccine containing tetanus toxoid, the risks of Guillain-Barre syndrome may be increased following Diphtheria and Tetanus Toxoids Adsorbed.

Apnea following vaccination has been observed in some infants born prematurely.

Syncope (fainting) has also been reported following vaccination with Diphtheria and Tetanus Toxoids Adsorbed. Procedures should be in place to prevent falling injury and manage syncopal reactions.

The most common local and systemic adverse reactions to Diphtheria and Tetanus Toxoids Adsorbed include transient fever, crying, loss of appetite; redness, swelling, and induration at the injection site; malaise, and pain. Other adverse reactions may occur. Vaccination with Diphtheria and Tetanus Toxoids Adsorbed may not protect all individuals.

Please see full Prescribing Information for Diphtheria and Tetanus Toxoids Adsorbed

Should you have any additional questions, please contact Sanofi Pasteur at 1-800-VACCINE (1-800-822-2463).

Regards,

Michael Laclair

Head of PPH and Boosters Vaccines

MAT-US-2203681-v1.0-05/2022